Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study).
Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Rodríguez-Martínez E, Urrutia-Pérez K, Urrutia-Pérez K, Quintana-Guerra J, Navarro-Rodríguez Z, Piñera-Martínez M, Rodríguez-Reinoso JL, Chávez-Chong CO, Baladrón-Castrillo I, Melo-Suárez G, Batista-Izquierdo A, Pupo-Micó A, Mora-Betancourt R, Bizet-Almeida J, Martínez-Rodríguez MC, Lobaina-Lambert L, Velázquez-Pérez VM, Soler-Díaz J, Laurencio-Vallina S, Meriño-Hechavarría T, Carmenaty-Campos N, Rodríguez-Montero E, Limonta-Fernández M, Alonso-Valdés M, Hernández-Rodríguez R, Pimentel-Vázquez E, Catasús-Álvarez KM, Cabrera-Núñez MV, Ayala-Ávila M, Muzio-González VL; ABDALA Research Group. Hernández-Bernal F, et al. Among authors: limonta fernandez m. Lancet Reg Health Am. 2023 May 5;21:100497. doi: 10.1016/j.lana.2023.100497. eCollection 2023 May. Lancet Reg Health Am. 2023. PMID: 37192953 Free PMC article.
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Navarro-Rodríguez Z, Piñera-Martínez M, Quintana-Guerra J, Urrutia-Pérez K, Urrutia-Pérez K, Chávez-Chong CO, Azor-Hernández JL, Rodríguez-Reinoso JL, Lobaina-Lambert L, Colina-Ávila E, Bizet-Almeida J, Rodríguez-Nuviola J, Del Valle-Piñera S, Ramírez-Domínguez M, Tablada-Ferreiro E, Alonso-Valdés M, Lemos-Pérez G, Guillén-Nieto GE, Palenzuela-Díaz A, Noa-Romero E, Limonta-Fernández M, Fernández-Ávila JM, Ali-Mros NA, Del Toro-Lahera L, Remedios-Reyes R, Ayala-Ávila M, Muzio-González VL. Hernández-Bernal F, et al. Among authors: limonta fernandez m. EClinicalMedicine. 2022 Apr;46:101383. doi: 10.1016/j.eclinm.2022.101383. Epub 2022 Apr 9. EClinicalMedicine. 2022. PMID: 35434578 Free PMC article.
Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study.
Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, Galbán-García E, Olivera-Nodarse Y, Morgado-Vega I, Dueñas-Carrera S, Pujol M, Hernández-Bernal F, Limonta-Fernández M, Guillén-Nieto G, Muzio-González VL, Ayala-Ávila M. Más-Bermejo PI, et al. Among authors: limonta fernandez m. Lancet Reg Health Am. 2022 Dec;16:100366. doi: 10.1016/j.lana.2022.100366. Epub 2022 Sep 24. Lancet Reg Health Am. 2022. PMID: 36185968 Free PMC article.
Correction to "Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study" [The Lancet Regional Health - Americas 2022; 16: 100366] https://doi.org/10.1016/j.lana.2022.100366.
Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, Galbán-García E, Olivera-Nodarse Y, Morgado-Vega I, Dueñas-Carrera S, Pujol M, Hernández-Bernal F, Limonta-Fernández M, Guillén-Nieto G, Muzio-González VL, Ayala-Ávila M. Más-Bermejo PI, et al. Among authors: limonta fernandez m. Lancet Reg Health Am. 2023 Feb;18:100422. doi: 10.1016/j.lana.2022.100422. Epub 2022 Dec 29. Lancet Reg Health Am. 2023. PMID: 36593764 Free PMC article.
Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors.
Sánchez Ramírez J, Bequet-Romero M, Morera Díaz Y, Hernández-Bernal F, de la Torre Santos A, Selman-Housein Bernal KH, Martín Bauta Y, Bermúdez Badell CH, Limonta Fernández M, Ayala Avila M. Sánchez Ramírez J, et al. Heliyon. 2018 Nov 2;4(11):e00906. doi: 10.1016/j.heliyon.2018.e00906. eCollection 2018 Nov. Heliyon. 2018. PMID: 30426104 Free PMC article.
An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen.
Limonta-Fernández M, Chinea-Santiago G, Martín-Dunn AM, Gonzalez-Roche D, Bequet-Romero M, Marquez-Perera G, González-Moya I, Canaan-Haden-Ayala C, Cabrales-Rico A, Espinosa-Rodríguez LA, Ramos-Gómez Y, Andujar-Martínez I, González-López LJ, de la Iglesia MP, Zamora-Sanchez J, Cruz-Sui O, Lemos-Pérez G, Cabrera-Herrera G, Valdes-Hernández J, Martinez-Diaz E, Pimentel-Vazquez E, Ayala-Avila M, Guillén-Nieto G. Limonta-Fernández M, et al. N Biotechnol. 2022 Dec 25;72:11-21. doi: 10.1016/j.nbt.2022.08.002. Epub 2022 Aug 8. N Biotechnol. 2022. PMID: 35953030 Free PMC article.
An update on Cuban biotech.
Buxadó JA, Limonta Fernández M, Guillén Nieto GE, Gómez RU, Ayala Ávila M. Buxadó JA, et al. Among authors: limonta fernandez m. Nat Biotechnol. 2024 Dec;42(12):1768-1770. doi: 10.1038/s41587-024-02458-y. Nat Biotechnol. 2024. PMID: 39663473 No abstract available.
Epidermal Growth Factor Intralesional Delivery in Chronic Wounds: The Pioneer and Standalone Technique for Reversing Wound Chronicity and Promoting Sustainable Healing.
Berlanga-Acosta J, Garcia-Ojalvo A, Fernández-Montequin J, Falcon-Cama V, Acosta-Rivero N, Guillen-Nieto G, Pujol-Ferrer M, Limonta-Fernandez M, Ayala-Avila M, Eriksson E. Berlanga-Acosta J, et al. Among authors: limonta fernandez m. Int J Mol Sci. 2024 Oct 10;25(20):10883. doi: 10.3390/ijms252010883. Int J Mol Sci. 2024. PMID: 39456666 Free PMC article. Review.
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1-2 Clinical Trial.
Lemos-Pérez G, Barrese-Pérez Y, Chacón-Quintero Y, Uranga-Piña R, Avila-Albuerne Y, Figueroa-García I, Calderín-Marín O, Gómez-Vázquez MM, Piñera-Martínez M, Chávez-Valdés S, Martínez-Rosales R, Ávila-Díaz L, Vázquez-Arteaga A, González-Formental H, Freyre-Corrales G, Coizeau-Rodríguez E, Limonta-Fernández M, Ayala-Avila M, Martínez-Díaz E, Pimentel-Vazquez E, Guillen G. Lemos-Pérez G, et al. Among authors: limonta fernandez m. Vaccines (Basel). 2024 Sep 1;12(9):1001. doi: 10.3390/vaccines12091001. Vaccines (Basel). 2024. PMID: 39340031 Free PMC article.
Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MEÑIQUE).
Hernández-Bernal F, Noa-Romero E, Quintana-Guerra J, Chávez-Chong CO, Martín-Bauta Y, Alvaré-Alvaré L, Salvato-Dueñas A, Felipe-Mallea D, Porta-Díaz M, Cruz-Sui O, Urrutia-Pérez K, Urrutia-Pérez K, Rodríguez-Reinoso JL, Alonso-Valdés M, Cinza-Estévez Z, Rodríguez-Triana A, Cruz-Gómez Y, Limonta-Fernández M, Rodríguez-Acosta M, Ayala-Ávila M, Muzio-González VL; ABDALA Group of Investigators. Hernández-Bernal F, et al. Among authors: limonta fernandez m. Vaccine. 2024 Sep 17;42(22):126223. doi: 10.1016/j.vaccine.2024.126223. Epub 2024 Aug 15. Vaccine. 2024. PMID: 39151232 Free article. Clinical Trial.
12 results